Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2) : clinical trials and investigations
Objective The objective of this study was to describe the rationale and design of two multinational phase 3 clinical trials of survodutide, an investigational glucagon and glucagon-like peptide-1 receptor dual agonist for the treatment of obesity with or without type 2 diabetes (T2D; SYNCHRONIZE-1 a...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
January 2025
|
| In: |
Obesity
Year: 2025, Volume: 33, Issue: 1, Pages: 67-77 |
| ISSN: | 1930-739X |
| DOI: | 10.1002/oby.24184 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/oby.24184 Verlag, kostenfrei, Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1002/oby.24184 
|
| Author Notes: | Sean Wharton, Carel W. le Roux, Mikhail N. Kosiborod, Elke Platz, Martina Brueckmann, Ania M. Jastreboff, Samina Ajaz Hussain, Sue D. Pedersen, Luiza Borowska, Anna Unseld, Isabel M. Kloer, Lee M. Kaplan, on behalf of the SYNCHRONIZE-1 and -2 trial committees and investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1925490661 | ||
| 003 | DE-627 | ||
| 005 | 20250717013541.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250513s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/oby.24184 |2 doi | |
| 035 | |a (DE-627)1925490661 | ||
| 035 | |a (DE-599)KXP1925490661 | ||
| 035 | |a (OCoLC)1528045332 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wharton, Sean |e VerfasserIn |0 (DE-588)1365462889 |0 (DE-627)1925491501 |4 aut | |
| 245 | 1 | 0 | |a Survodutide for treatment of obesity |b rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2) : clinical trials and investigations |c Sean Wharton, Carel W. le Roux, Mikhail N. Kosiborod, Elke Platz, Martina Brueckmann, Ania M. Jastreboff, Samina Ajaz Hussain, Sue D. Pedersen, Luiza Borowska, Anna Unseld, Isabel M. Kloer, Lee M. Kaplan, on behalf of the SYNCHRONIZE-1 and -2 trial committees and investigators |
| 264 | 1 | |c January 2025 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Erstmals veröffentlicht: 04. November 2024 | ||
| 500 | |a Gesehen am 13.05.2025 | ||
| 520 | |a Objective The objective of this study was to describe the rationale and design of two multinational phase 3 clinical trials of survodutide, an investigational glucagon and glucagon-like peptide-1 receptor dual agonist for the treatment of obesity with or without type 2 diabetes (T2D; SYNCHRONIZE-1 and -2). Methods In these ongoing double-blind trials, participants were randomized to once-weekly subcutaneous injections of survodutide or placebo added to lifestyle modification. Survodutide doses are uptitrated to 3.6 or 6.0 mg, and dose flexibility is permitted. Participants (n = 726) in SYNCHRONIZE-1 (NCT06066515) have a baseline BMI ≥ 30 kg/m2 or ≥27 kg/m2 with at least one obesity-related complication but without T2D; participants (n = 755) in SYNCHRONIZE-2 (NCT06066528) have a baseline BMI ≥ 27 kg/m2 and T2D. The primary endpoints are percentage change in body weight and proportion of participants achieving ≥5% body weight reduction from baseline to week 76. Secondary endpoints include change in systolic blood pressure and measures of glycemia. A SYNCHRONIZE-1 substudy is evaluating changes in body composition and liver fat content using magnetic resonance imaging. Conclusions These trials are designed to provide robust evaluation of the efficacy, safety, and tolerability of survodutide for the treatment of obesity in the presence or absence of T2D. | ||
| 700 | 1 | |a le Roux, Carel W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kosiborod, Mikhail N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Platz, Elke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brückmann, Martina |d 1970- |e VerfasserIn |0 (DE-588)121145069 |0 (DE-627)705257290 |0 (DE-576)292557736 |4 aut | |
| 700 | 1 | |a Jastreboff, Ania M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ajaz Hussain, Samina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pedersen, Sue D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Borowska, Luiza |e VerfasserIn |4 aut | |
| 700 | 1 | |a Unseld, Anna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kloer, Isabel M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kaplan, Lee M. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Obesity |d Hoboken, NJ : Wiley, 2006 |g 33(2025), 1 vom: Jan., Seite 67-77 |h Online-Ressource |w (DE-627)32448545X |w (DE-600)2027211-X |w (DE-576)306829053 |x 1930-739X |7 nnas |a Survodutide for treatment of obesity rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2) : clinical trials and investigations |
| 773 | 1 | 8 | |g volume:33 |g year:2025 |g number:1 |g month:01 |g pages:67-77 |g extent:11 |a Survodutide for treatment of obesity rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2) : clinical trials and investigations |
| 856 | 4 | 0 | |u https://doi.org/10.1002/oby.24184 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://onlinelibrary.wiley.com/doi/abs/10.1002/oby.24184 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250513 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 121145069 |a Brückmann, Martina |m 121145069:Brückmann, Martina |d 60000 |d 61000 |e 60000PB121145069 |e 61000PB121145069 |k 0/60000/ |k 1/60000/61000/ |p 5 | ||
| 999 | |a KXP-PPN1925490661 |e 4723930841 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Sean Wharton, Carel W. le Roux, Mikhail N. Kosiborod, Elke Platz, Martina Brueckmann, Ania M. Jastreboff, Samina Ajaz Hussain, Sue D. Pedersen, Luiza Borowska, Anna Unseld, Isabel M. Kloer, Lee M. Kaplan, on behalf of the SYNCHRONIZE-1 and -2 trial committees and investigators"]},"relHost":[{"part":{"pages":"67-77","volume":"33","text":"33(2025), 1 vom: Jan., Seite 67-77","issue":"1","extent":"11","year":"2025"},"name":{"displayForm":["the North American Association for the Study of Obesity"]},"pubHistory":["Volume 14, issue 1 (January 2006)-"],"disp":"Survodutide for treatment of obesity rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2) : clinical trials and investigationsObesity","origin":[{"dateIssuedDisp":"2006-","publisher":"Wiley ; NAASO ; Nature Publishing Group","publisherPlace":"Hoboken, NJ ; Silver Spring, Md. ; Cambridge, Mass.","dateIssuedKey":"2006"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title_sort":"Obesity","title":"Obesity"}],"note":["Gesehen 10.03.25"],"recId":"32448545X","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["32448545X"],"issn":["1930-739X"],"zdb":["2027211-X"]},"language":["eng"]}],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"January 2025"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Erstmals veröffentlicht: 04. November 2024","Gesehen am 13.05.2025"],"title":[{"title_sort":"Survodutide for treatment of obesity","title":"Survodutide for treatment of obesity","subtitle":"rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2) : clinical trials and investigations"}],"person":[{"family":"Wharton","display":"Wharton, Sean","roleDisplay":"VerfasserIn","given":"Sean","role":"aut"},{"given":"Carel W.","role":"aut","family":"le Roux","display":"le Roux, Carel W.","roleDisplay":"VerfasserIn"},{"display":"Kosiborod, Mikhail N.","family":"Kosiborod","roleDisplay":"VerfasserIn","role":"aut","given":"Mikhail N."},{"roleDisplay":"VerfasserIn","family":"Platz","display":"Platz, Elke","given":"Elke","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Brückmann, Martina","family":"Brückmann","given":"Martina","role":"aut"},{"given":"Ania M.","role":"aut","roleDisplay":"VerfasserIn","display":"Jastreboff, Ania M.","family":"Jastreboff"},{"family":"Ajaz Hussain","display":"Ajaz Hussain, Samina","roleDisplay":"VerfasserIn","role":"aut","given":"Samina"},{"roleDisplay":"VerfasserIn","display":"Pedersen, Sue D.","family":"Pedersen","role":"aut","given":"Sue D."},{"display":"Borowska, Luiza","family":"Borowska","roleDisplay":"VerfasserIn","given":"Luiza","role":"aut"},{"given":"Anna","role":"aut","roleDisplay":"VerfasserIn","display":"Unseld, Anna","family":"Unseld"},{"given":"Isabel M.","role":"aut","roleDisplay":"VerfasserIn","display":"Kloer, Isabel M.","family":"Kloer"},{"role":"aut","given":"Lee M.","display":"Kaplan, Lee M.","family":"Kaplan","roleDisplay":"VerfasserIn"}],"recId":"1925490661","language":["eng"],"id":{"eki":["1925490661"],"doi":["10.1002/oby.24184"]},"physDesc":[{"extent":"11 S."}]} | ||
| SRT | |a WHARTONSEASURVODUTID2025 | ||